...
首页> 外文期刊>Journal of Cancer Research and Clinical Oncology >ERα negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor
【24h】

ERα negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor

机译:ERα阴性乳腺癌细胞通过与HDAC抑制剂和DNMT抑制剂联合治疗恢复对内分泌治疗的反应

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose Estrogen receptor α (ERα) mediates the growth stimulation of estrogen in breast cancer cells and is a useful predictive factor for response to endocrine therapy. It is reported that ERα was induced in ERα negative breast cancer cells by both DNA methyltransferase-1 (DNMT1) inhibitor 5-aza-2′-deoxycytidine (AZA) and histone deacetylase (HDAC) inhibitor trichostatin A (TSA). However, whether the breast cancer cells with induced ERα restore response to endocrine therapy requires to be further researched.
机译:目的雌激素受体α(ERα)介导乳腺癌细胞中雌激素的生长刺激,是对内分泌治疗反应的有用预测因子。据报道,DNA甲基转移酶-1(DNMT1)抑制剂5-氮杂2'-脱氧胞苷(AZA)和组蛋白脱乙酰基酶(HDAC)抑制剂曲古抑菌素A(TSA)均可在ERα阴性乳腺癌细胞中诱导ERα。然而,诱导ERα的乳腺癌细胞是否能恢复对内分泌治疗的反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号